Giovanni Lentini

List of Publications by Year
in descending order

118	3,113	186265	182427
papers	citations	28 h-index	51 g-index

125	125	125	4035
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Personalized Medicine in Mitochondrial Health and Disease: Molecular Basis of Therapeutic Approaches Based on Nutritional Supplements and Their Analogs. Molecules, 2022, 27, 3494.	3.8	18
2	Synthesis and Evaluation of Voltageâ€Gated Sodium Channel Blocking Pyrroline Derivatives Endowed with Both Antiarrhythmic and Antioxidant Activities. ChemMedChem, 2021, 16, 578-588.	3.2	6
3	Lubeluzole: from anti-ischemic drug to preclinical antidiarrheal studies. Pharmacological Reports, 2021, 73, 172-184.	3.3	6
4	Molecular Simplification of Natural Products: Synthesis, Antibacterial Activity, and Molecular Docking Studies of Berberine Open Models. Biomedicines, 2021, 9, 452.	3.2	8
5	Inverse Virtual Screening for the rapid re-evaluation of the presumed biological safe profile of natural products. The case of steviol from Stevia rebaudiana glycosides on farnesoid X receptor (FXR). Bioorganic Chemistry, 2021, 111, 104897.	4.1	3
6	Xanthenylacetic Acid Derivatives Effectively Target Lysophosphatidic Acid Receptor 6 to Inhibit Hepatocellular Carcinoma Cell Growth. ChemMedChem, 2021, 16, 2121-2129.	3.2	9
7	Densely Functionalized 2-Methylideneazetidines: Evaluation as Antibacterials. Molecules, 2021, 26, 3891.	3.8	4
8	Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study. Journal of Chemical Information and Modeling, 2021, 61, 4758-4770.	5.4	33
9	Bioisosteric Modification of To042: Synthesis and Evaluation of Promising Useâ€Dependent Inhibitors of Voltageâ€Gated Sodium Channels. ChemMedChem, 2021, 16, 3588-3599.	3.2	3
10	Functionalized Dendrimer Platforms as a New Forefront Arsenal Targeting SARS-CoV-2: An Opportunity. Pharmaceutics, 2021, 13, 1513.	4.5	14
11	CHANNELOPATHIES AND RELATED DISORDERS. Neuromuscular Disorders, 2021, 31, S117.	0.6	0
12	Targeting Penicillium expansum GMC Oxidoreductase with High Affinity Small Molecules for Reducing Patulin Production. Biology, 2021, 10, 21.	2.8	5
13	Novel lysophosphatidic acid receptor 6 antagonists inhibit hepatocellular carcinoma growth through affecting mitochondrial function. Journal of Molecular Medicine, 2020, 98, 179-191.	3.9	22
14	Structure-Based Identification and Design of Angiotensin Converting Enzyme-Inhibitory Peptides from Whey Proteins. Journal of Agricultural and Food Chemistry, 2020, 68, 541-548.	5.2	18
15	Human ether-Ã-go-go-related potassium channel: exploring SAR to improve drug design. Drug Discovery Today, 2020, 25, 344-366.	6.4	33
16	Ultrasound and deep eutectic solvents: An efficient combination to tune the mechanism of steviol glycosides extraction. Ultrasonics Sonochemistry, 2020, 69, 105255.	8.2	30
17	From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies. Molecules, 2020, 25, 3320.	3.8	21
18	Optimization of Microwave-Assisted Extraction of Antioxidants from Bamboo Shoots of Phyllostachys pubescens. Molecules, 2020, 25, 215.	3.8	25

#	Article	IF	Citations
19	Repurposing therapeutic agents and herbal medicines to defeat viral nemesis. Drug Development Research, 2020, 81, 641-642.	2.9	3
20	COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help. Molecules, 2020, 25, 1834.	3.8	37
21	Targeting the pregnane X receptor using microbial metabolite mimicry. EMBO Molecular Medicine, 2020, 12, e11621.	6.9	53
22	The therapeutic power of green. Schizophrenia Research, 2019, 210, 310.	2.0	1
23	Comment on â€œIn Situ Derivatization of (RS)-Mexiletine and Enantioseparation Using Micellar Liquid Chromatography: A Green Approachâ€• ACS Sustainable Chemistry and Engineering, 2019, 7, 6424-6425.	6.7	2
24	(S)-Ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5-methylenedioxyphenyl)propanoate. MolBank, 2019, 2019, M1049.	0.5	0
25	A Focus on the Synthesis and Pharmacokinetics of Tocainide and its Analogues. Current Medicinal Chemistry, 2019, 25, 5822-5834.	2.4	3
26	The Crystal Structure of N-[(2E)-3-(4-Chlorophenyl)prop-2-en-1-yl]-4-methoxy-N-methylbenzenesulfonamide. Journal of Chemical Crystallography, 2019, 49, 87-91.	1.1	2
27	Pyrroline Derivatives of Mexiletine-Like Compounds Have Dual Activity as Use-Dependent Sodium Channel Blockers and Antioxidant. Biophysical Journal, 2018, 114, 634a.	0.5	0
28	Positional isomers of mannoseâ€“quinoline conjugates and their copper complexes: exploring the biological activity. New Journal of Chemistry, 2018, 42, 8882-8890.	2.8	7
29	Molecular Insights into hERG Potassium Channel Blockade by Lubeluzole. Cellular Physiology and Biochemistry, 2018, 45, 2233-2245.	1.6	10
30	Plant-Derived Anticancer Agents: Lessons from the Pharmacology of Geniposide and Its Aglycone, Genipin. Biomedicines, 2018, 6, 39.	3.2	60
31	Antimicrobial and Antibiofilm Activities of Citrus Water-Extracts Obtained by Microwave-Assisted and Conventional Methods. Biomedicines, 2018, 6, 70.	3.2	29
32	Old Drug Scaffold, New Activity: Thalidomideâ€Correlated Compounds Exert Different Effects on Breast Cancer Cell Growth and Progression. ChemMedChem, 2017, 12, 381-389.	3.2	44
33	2-Arylazetidines as ligands for nicotinic acetylcholine receptors. Chemistry of Heterocyclic Compounds, 2017, 53, 329-334.	1.2	5
34	The trivial names of citrus limonoids. Food Chemistry, 2017, 225, 288.	8.2	0
35	New doxorubicin nanocarriers based on cyclodextrins. Investigational New Drugs, 2017, 35, 539-544.	2.6	19
36	Ligand efficiency metrics in drug discovery: the pros and cons from a practical perspective. Expert Opinion on Drug Discovery, 2017, 12, 1087-1104.	5.0	75

#	Article	IF	Citations
37	Nitro-substituted tetrahydroindolizines and homologs: Design, kinetics, and mechanism of Î±-glucosidase inhibition. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3980-3986.	2.2	23
38	Discovery of a new mexiletine-derived agonist of the hERG K + channel. Biophysical Chemistry, 2017, 229, 62-67.	2.8	9
39	Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential. Frontiers in Pharmacology, 2017, 8, 907.	3.5	12
40	A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma. Current Medicinal Chemistry, 2017, 24, 2736-2744.	2.4	71
41	The Chemistry and Pharmacology of Citrus Limonoids. Molecules, 2016, 21, 1530.	3.8	121
42	Stereoselective Modulation of Pâ€Glycoprotein by Chiral Small Molecules. ChemMedChem, 2016, 11, 93-101.	3.2	10
43	Synthesis and evaluation of berberine derivatives and analogs as potential antiacetylcholinesterase and antioxidant agents. Phytochemistry Letters, 2016, 18, 150-156.	1.2	23
44	Synthesis, antiarrhythmic activity, and toxicological evaluation of mexiletine analogues. European Journal of Medicinal Chemistry, 2016, 121, 300-307.	5.5	19
45	The chemosensitizing agent lubeluzole binds calmodulin and inhibits Ca 2+ /calmodulin-dependent kinase II. European Journal of Medicinal Chemistry, 2016, 116, 36-45.	5.5	12
46	Recent Trends in the Discovery of Small Molecule Blockers of Sodium Channels. Current Medicinal Chemistry, 2016, 23, 2289-2332.	2.4	8
47	Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite mâ€hydroxymexiletine. Pharmacology Research and Perspectives, 2015, 3, e00160.	2.4	35
48	Insights on Molecular Determinants of hERG K+ Channel Inhibition: Design, Synthesis, and Biological Evaluation of Lubeluzole Derivatives. Biophysical Journal, 2015, 108, 582a.	0.5	2
49	Did Ebola Survivors Use Plant Medicines, and if so, Which Ones?. Phytotherapy Research, 2015, 29, 632-632.	5.8	2
50	Antioxidant Activity of Uva di Troia Canosina: Comparison of Two Extraction Methods. Clinical Immunology, Endocrine and Metabolic Drugs, 2015, 2, 8-12.	0.3	8
51	Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres. Frontiers in Pharmacology, 2015, 6, 155.	3.5	4
52	Plotting intersections. Nature Methods, 2015, 12, 281-281.	19.0	3
53	Enzymatic Resolution of Î±â€Methyleneparaconic Acids and Evaluation of their Biological Activity. Chirality, 2015, 27, 239-246.	2.6	3
54	Ebola therapy: Developing new drugs or repurposing old ones?. International Journal of Cardiology, 2015, 179, 325.	1.7	6

#	Article	IF	Citations
55	The Therapeutic Potential of Rutin for Diabetes: An Update. Mini-Reviews in Medicinal Chemistry, 2015, 15, 524-528.	2.4	66
56	Preparation of (â^')-(R)-2-(2,3,4,5,6-pentafluorophenoxy)-2-(phenyl-d5)acetic acid: an efficient 1H NMR chiral solvating agent for direct enantiomeric purity evaluation of quinoline-containing antimalarial drugs. Tetrahedron: Asymmetry, 2014, 25, 1605-1611.	1.8	5
57	Microchip capillary electrophoresisâ€“electrospray ionization mass spectrometry analysis of paracetamol metabolites in human urine: An intriguing case. Journal of Chromatography A, 2014, 1327, 160.	3.7	4
58	A convenient synthesis of lubeluzole and its enantiomer: Evaluation as chemosensitizing agents on human ovarian adenocarcinoma and lung carcinoma cells. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4820-4823.	2.2	12
59	P.12.12 Preclinical in vitro and in vivo evaluation of sodium channel blockers as possible alternative to mexiletine in the treatment of myotonia. Neuromuscular Disorders, 2013, 23, 808.	0.6	0
60	N-(Phenoxyalkyl)amides as MT1 and MT2 ligands: Antioxidant properties and inhibition of Ca2+/CaM-dependent kinase II. Bioorganic and Medicinal Chemistry, 2013, 21, 847-851.	3.0	29
61	Combined Modifications of Mexiletine Pharmacophores for New Lead Blockers of Nav1.4 Channels. Biophysical Journal, 2013, 104, 344-354.	0.5	29
62	Searching for new antiarrhythmic agents: Evaluation ofÂmeta-hydroxymexiletine enantiomers. European Journal of Medicinal Chemistry, 2013, 65, 511-516.	5.5	19
63	Microwave-Assisted Synthesis of <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>Â±</mml:mo><mml:mo) Tj ETQq1 1 0.784314 rgBT /Overlock xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mn>5</mml:mn></mml:msub></mml:mrow></mml:math>, Optical Resolution, and Absolute Configuration Determination. Journal of Chemistry, 2013, 2013, 1-6.	1.9	3
64	Molecular Dissection of Lubeluzole Useâ€“Dependent Block of Voltage-Gated Sodium Channels Discloses New Therapeutic Potentials. Molecular Pharmacology, 2013, 83, 406-415.	2.3	14
65	Capillary Zone Electrophoresis for Separation and Quantitative Determination of Mexiletine and its Main Phase I Metabolites. Drug Metabolism Letters, 2013, 7, 52-57.	0.8	2
66	Recent Trends and Future Prospects in Computational GPCR Drug Discovery: From Virtual Screening to Polypharmacology. Current Topics in Medicinal Chemistry, 2013, 13, 1069-1097.	2.1	27
67	Stereospecific Synthesis of m-Hydroxymexiletine Enantiomers. Drug Metabolism Letters, 2013, 6, 182-186.	0.8	8
68	Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity'?. Nature Reviews Drug Discovery, 2012, 11, 730-730.	46.4	2
69	Crystal structure of N-(2-{[(2E)-3-(4-chlorophenyl)-2-propenyl]-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 192 Td ((methyl)ammo phosphate â€" methanol (1:1), [C26H30ClN2SO4][H2PO4] Â· CH4O. Zeitschrift Fur Kristallographie - New Crystal Structures, 2012, 227, .	0.3	0
70	An Improved Synthesis of m-Hydroxymexiletine, a Potent Mexiletine Metabolite. Drug Metabolism Letters, 2012, 6, 124-128.	0.8	3
71	Molecular Determinants of Human Voltage-Gated Sodium Channels Blockade by Lubeluzole. Biophysical Journal, 2012, 102, 323a.	0.5	0
72	Molecular insights into the local anesthetic receptor within voltage-gated sodium channels using hydroxylated analogs of mexiletine. Frontiers in Pharmacology, 2012, 3, 17.	3.5	28

#	Article	IF	Citations
73	Phytochemical, Antioxidant and Antiâ€Î±â€glucosidase Activity Evaluations of Bergenia cordifolia. Phytotherapy Research, 2012, 26, 908-914.	5.8	51
74	Synthesis and Toxicopharmacological Evaluation of m-Hydroxymexiletine, the First Metabolite of Mexiletine More Potent Than the Parent Compound on Voltage-Gated Sodium Channels. Journal of Medicinal Chemistry, 2012, 55, 1418-1422.	6.4	28
75	An Improved Synthesis of m-Hydroxymexiletine, a Potent Mexiletine Metabolite. Drug Metabolism Letters, 2012, 6, 124-128.	0.8	12
76	An improved synthesis of m-hydroxymexiletine, a potent mexiletine metabolite. Drug Metabolism Letters, 2012, 6, 124-8.	0.8	1
77	P4.45 Evaluation of the dual action of new derivatives of mexiletine as use-dependent sodium channel blockers and antioxidant: potential therapeutic application in neuromuscular disorders. Neuromuscular Disorders, 2011, 21, 718.	0.6	0
78	Facile routes for the preparation of 3,4â€disubstituted 1,3â€oxazolidines and 1,2,5â€trisubstituted imidazolidinâ€4â€ones. Journal of Heterocyclic Chemistry, 2011, 48, 261-266.	2.6	5
79	New N-(phenoxydecyl)phthalimide derivatives displaying potent inhibition activity towards Î±-glucosidase. Bioorganic and Medicinal Chemistry, 2010, 18, 5903-5914.	3.0	42
80	Chiral Aryloxyalkylamines: Selective 5â€HT_{1B/1D} Activation and Analgesic Activity. ChemMedChem, 2010, 5, 696-704.	3.2	14
81	Synthesis and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogs. Chirality, 2010, 22, 299-307.	2.6	19
82	Hydroxylated Analogs of Mexiletine as Tools for Structuralâ€Requirements Investigation of the Sodium Channel Blocking Activity. Archiv Der Pharmazie, 2010, 343, 325-332.	4.1	12
83	First synthesis and full characterization of mexiletine N-carbonyloxy Î²-d-glucuronide. Tetrahedron Letters, 2010, 51, 5265-5268.	1.4	13
84	Design, synthesis, and pharmacological effects of structurally simple ligands for MT1 and MT2 melatonin receptors. Bioorganic and Medicinal Chemistry, 2010, 18, 6496-6511.	3.0	32
85	Molecular determinants of stateâ€dependent block of voltageâ€gated sodium channels by pilsicainide. British Journal of Pharmacology, 2010, 160, 1521-1533.	5.4	18
86	Microwave-Assisted Synthesis of KN-93, a Potent and Selective Inhibitor of CaÂ²+/Calmoduline-Dependent Protein Kinase II. Synthesis, 2010, 2010, 4193-4198.	2.3	1
87	Fpocket: An open source platform for ligand pocket detection. BMC Bioinformatics, 2009, 10, 168.	2.6	980
88	One-step synthesis of homochiral O-aryl and O-heteroaryl mandelic acids and their use as efficient 1H NMR chiral solvating agents. Tetrahedron: Asymmetry, 2009, 20, 1984-1991.	1.8	33
89	G.P.14.11 Newly synthesized mexiletine and tocainide analogues are potent use-dependent blockers of skeletal muscle sodium channels: Potential implication for the antimyotonic activity. Neuromuscular Disorders, 2009, 19, 646.	0.6	2
90	Facile Entry to Ethyl Tetrahydro-1H-pyrrolizin-7a(5H)-ylacetate: a Versatile Pharmaceutical Intermediate. Heterocycles, 2008, 75, 2193.	0.7	11

#	Article	IF	Citations
91	Pilsicainide and Its Oxymethylene Analog: Facile Alternative Syntheses and in vitro Testing on Human Skeletal Muscle Sodium Channels. Heterocycles, 2007, 71, 2011.	0.7	4
92	Synthesis and Biological Evaluation of Chiral Î±-Aminoanilides with Central Antinociceptive Activity. Journal of Medicinal Chemistry, 2007, 50, 1907-1915.	6.4	11
93	Synthesis of (R)-, (S)-, and (RS)-hydroxymethylmexiletine, one of the major metabolites of mexiletine. Tetrahedron: Asymmetry, 2007, 18, 2409-2417.	1.8	35
94	Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents. British Journal of Pharmacology, 2006, 149, 300-310.	5.4	26
95	Facile, alternative route to Lubeluzole, its enantiomer, and the racemate. Chirality, 2006, 18, 227-231.	2.6	26
96	Stereospecific synthesis of ?para-hydroxymexiletine? and sodium channel blocking activity evaluation. Chirality, 2004, 16, 72-78.	2.6	26
97	New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse. Neuromuscular Disorders, 2004, 14, 405-416.	0.6	27
98	Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 318-327.	3.0	29
99	Trivial, Common, and Systematic Chemical Names. Journal of Chemical Education, 2003, 80, 487.	2.3	1
100	Optically Active Mexiletine Analogues as Stereoselective Blockers of Voltage-Gated Na+ Channels. Journal of Medicinal Chemistry, 2003, 46, 5238-5248.	6.4	57
101	Optimal Requirements for High Affinity and Use-Dependent Block of Skeletal Muscle Sodium Channel by N-Benzyl Analogs of Tocainide-Like Compounds. Molecular Pharmacology, 2003, 64, 932-945.	2.3	30
102	On the Stereochemistry of 'Natural' Amino Acids (re J. Chem. Educ. 2000, 77, 48-49). Journal of Chemical Education, 2002, 79, 558.	2.3	0
103	Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo. British Journal of Pharmacology, 2001, 134, 1523-1531.	5.4	19
104	Facile entry to (?)-(R)- and (+)-(S)-mexiletine. , 2000, 12, 103-106.		29
105	Stereospecific synthesis of mexiletine and related compounds: Mitsunobu versus Williamson reaction. Tetrahedron: Asymmetry, 2000, 11, 3619-3634.	1.8	47
106	Homologation of mexiletine alkyl chain and stereoselective blockade of skeletal muscle sodium channels. European Journal of Medicinal Chemistry, 2000, 35, 147-156.	5.5	15
107	Synthesis of New 2,6-Prolylxylidide Analogues of Tocainide as Stereoselective Blockers of Voltage-Gated Na+ Channels with Increased Potency and Improved Use-Dependent Activity. Journal of Medicinal Chemistry, 2000, 43, 3792-3798.	6.4	21
108	Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels. Molecular Pharmacology, 2000, 57, 268-77.	2.3	41

#	Article	IF	Citations
109	Increased hindrance on the chiral carbon atom of mexiletine enhances the block of rat skeletal muscle Na+ channels in a model of myotonia induced by ATX. British Journal of Pharmacology, 1999, 128, 1165-1174.	5.4	14
110	Contribution to the study of 2-aryloxy-1-phenyl- and 2-aryloxy-2-phenylethanols. Differentiation by mass spectrometry.. Journal of Mass Spectrometry, 1998, 33, 486-487.	1.6	3
111	Therapeutic effects of tocainide and mexiletine analogs on myotonic MTO and ADR mice. Neuromuscular Disorders, 1997, 7, 447.	0.6	0
112	Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356, 777-787.	3.0	34
113	Evaluation of the antimyotonic activity of mexiletine and some new analogs on sodium currents of single muscle fibers and on the abnormal excitability of the myotonic ADR mouse. Journal of Pharmacology and Experimental Therapeutics, 1997, 282, 93-100.	2.5	28
114	Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 352, 653-661.	3.0	41
115	Stereospecific synthesis and absolute configuration of mexiletine. Chirality, 1994, 6, 590-595.	2.6	29
116	Stereoselectivity in central analgesic action of tocainide and its analogs. Chirality, 1993, 5, 135-142.	2.6	13
117	Pharmacological differences between R(-) and S(+) tocainide*1. Pharmacological Research, 1992, 26, 91.	7.1	1
118	The effects of tocainide and its chiral analogs on sodium channels of human muscle. Pharmacological Research, 1990, 22, 95-96.	7.1	1